These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31006312)

  • 1. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
    Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
    Crotti L; Neves R; Dagradi F; Musu G; Giannetti F; Bos JM; Barbieri M; Cerea P; Giovenzana FLF; Torchio M; Mura M; Gnecchi M; Conte G; Auricchio A; Sala L; Odening KE; Ackerman MJ; Schwartz PJ
    Circulation; 2024 Aug; 150(7):531-543. PubMed ID: 38939955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
    Yang Y; Lv TT; Li SY; Zhang P
    J Cardiovasc Electrophysiol; 2021 Nov; 32(11):3057-3067. PubMed ID: 34427958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
    Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
    Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Architectural T-Wave Analysis and Identification of On-Therapy Breakthrough Arrhythmic Risk in Type 1 and Type 2 Long-QT Syndrome.
    Sugrue A; Rohatgi RK; Noseworthy PA; Kremen V; Bos JM; Qiang B; Sapir Y; Attia ZI; Scott CG; Brady P; Asirvatham SJ; Friedman PA; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2017 Nov; 10(11):. PubMed ID: 29141844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
    Shimizu W; Antzelevitch C
    Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
    Mazzanti A; Maragna R; Faragli A; Monteforte N; Bloise R; Memmi M; Novelli V; Baiardi P; Bagnardi V; Etheridge SP; Napolitano C; Priori SG
    J Am Coll Cardiol; 2016 Mar; 67(9):1053-1058. PubMed ID: 26940925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome.
    Wong JA; Gula LJ; Klein GJ; Yee R; Skanes AC; Krahn AD
    Circ Arrhythm Electrophysiol; 2010 Apr; 3(2):120-5. PubMed ID: 20071715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
    Shimizu W; Antzelevitch C
    J Am Coll Cardiol; 2000 Mar; 35(3):778-86. PubMed ID: 10716483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular basis for the therapy of the long QT syndrome.
    Priori SG; Napolitano C; Schwartz PJ
    Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-specific effect of beta-adrenergic blockade on corrected QT interval in the long QT syndrome.
    Extramiana F; Maison-Blanche P; Denjoy I; De Jode P; Messali A; Labbé JP; Leenhardt A
    Ann Noninvasive Electrocardiol; 2013 Jul; 18(4):399-408. PubMed ID: 23879280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pronounced Shortening of QT Interval With Mexiletine Infusion Test in Patients With Type 3 Congenital Long QT Syndrome.
    Funasako M; Aiba T; Ishibashi K; Nakajima I; Miyamoto K; Inoue Y; Okamura H; Noda T; Kamakura S; Anzai T; Noguchi T; Yasuda S; Miyamoto Y; Fukushima Kusano K; Ogawa H; Shimizu W
    Circ J; 2016; 80(2):340-5. PubMed ID: 26632536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome.
    Noda T; Takaki H; Kurita T; Suyama K; Nagaya N; Taguchi A; Aihara N; Kamakura S; Sunagawa K; Nakamura K; Ohe T; Horie M; Napolitano C; Towbin JA; Priori SG; Shimizu W
    Eur Heart J; 2002 Jun; 23(12):975-83. PubMed ID: 12069453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mexiletine in the management of long QT syndrome.
    Li G; Zhang L
    J Electrocardiol; 2018; 51(6):1061-1065. PubMed ID: 30497731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mexiletine on long QT syndrome model.
    Wang HW; Zheng YQ; Yang ZF; Li CZ; Liu YM
    Acta Pharmacol Sin; 2003 Apr; 24(4):316-20. PubMed ID: 12676070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response.
    Vyas H; Hejlik J; Ackerman MJ
    Circulation; 2006 Mar; 113(11):1385-92. PubMed ID: 16534005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
    Walker BD; Krahn AD; Klein GJ; Skanes AC; Yee R; Wang J; Hegele RA
    Can J Cardiol; 2005 Jan; 21(1):33-8. PubMed ID: 15685300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.